Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

SU5614

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Pfizer

Drug class:

c-KIT inhibitor, FLT3 inhibitor, VEGFR-2 inhibitor

Related drugs:

‹

dasatinib (215)

sunitinib (139)

lenvatinib (90)

ripretinib (11)

pexidartinib (6)

BAY 57- 9352 (0)

quizartinib (40)

flonoltinib (0)

rivoceranib (82)

ramucirumab (59)

pegdinetanib (0)

›

FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	SU5614 Sensitive: D – Preclinical SU5614 Sensitive : D	SU5614 Sensitive: D – Preclinical SU5614 Sensitive : D
FLT3 NPOS + FLT3 D835N	Acute Myelogenous Leukemia	FLT3 NPOS + FLT3 D835N	Acute Myelogenous Leukemia	SU5614 Resistant: D – Preclinical SU5614 Resistant : D	SU5614 Resistant: D – Preclinical SU5614 Resistant : D
FLT3 D835N	Acute Myelogenous Leukemia	FLT3 D835N	Acute Myelogenous Leukemia	SU5614 Resistant: D – Preclinical SU5614 Resistant : D	SU5614 Resistant: D – Preclinical SU5614 Resistant : D
FLT3 V592A + FLT3 D835N	Acute Myelogenous Leukemia	FLT3 V592A + FLT3 D835N	Acute Myelogenous Leukemia	SU5614 Resistant: D – Preclinical SU5614 Resistant : D	SU5614 Resistant: D – Preclinical SU5614 Resistant : D
FLT3 D835Y	Acute Myelogenous Leukemia	FLT3 D835Y	Acute Myelogenous Leukemia	SU5614 Sensitive: D – Preclinical SU5614 Sensitive : D	SU5614 Sensitive: D – Preclinical SU5614 Sensitive : D
FLT3 G697R	Acute Myelogenous Leukemia	FLT3 G697R	Acute Myelogenous Leukemia	SU5614 Sensitive: D – Preclinical SU5614 Sensitive : D	SU5614 Sensitive: D – Preclinical SU5614 Sensitive : D